Bevacizumab (Bev) in combination with XELOX or FOLFOX-4: updated efficacy results from XELOX-1 / NO16966, a randomized phase III trial in first-line metastatic colorectal…
XELOX-1/NO16966, a randomized phase III trial of first-line XELOX vs. FOLFOX-4 for patients with metastatic colorectal cancer (MCRC): Updated overall survival results Cassidy…
XELOX vs. FOLFOX4: survival and response results from XELOX-1 / NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer…
A Report from ASCO 2007 First-Line Metastatic Colorectal Cancer Edward Chu, MD Professor, Medicine & Pharmacology Chief, Section of Medical Oncology Deputy Director,…